Loading…
Employees: 58
Size Daiken Biomedical (7780.TW) is a Taiwan Health Care company (Pharmaceuticals: Other) with a market value of $352M, the 585th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$14.45 on 6 Nov 2026.
Performance Over six months the shares fell 23.5%, against -21.2% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth The operating margin is 18.0% (peer median 10.8%).
Valuation It trades at 3.0× enterprise value to sales against a peer median of 2.3× (9th most expensive of 19).
| TTM | FY2025 | |
|---|---|---|
| Revenue | NT$2.19B | NT$1.90B |
| Revenue growth | — | — |
| Gross profit | NT$1.35B | NT$1.21B |
| EBITDA | NT$401M | NT$295M |
| Net income | NT$425M | NT$338M |
| Free cash flow | NT$268M | NT$270M |
| Capital expenditure | NT$139M | NT$5.16M |
| Total debt | NT$118M | NT$123M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7780.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.5% | -8.4% | 11th highest of 21 |
| 6-month return | -23.5% | -21.2% | 9th lowest of 21 |
| Distance from 52-week high | -50.9% | -38.2% | 3rd lowest of 21 |
| Operating margin | 18.0% | 10.8% | 8th highest of 20 |
| EV / Sales | 3.0× | 2.3× | 9th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 0.3% | 2.4% | 6th least demanding of 15 |
| EV / EBITDA | 16.2× | 5.2× | 2nd most expensive of 5 |
| Net debt / EBITDA | -12.8× | -1.6× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Daiken Biomedical 7780.TW | Taiwan | $352M | -24% | n/a | 18% | 3.0× | 0.3% | n/a |
| Zhejiang Xinguang Pharmaceutical 300519.SZ | China | $349M | -11% | +5% | 27% | 5.8× | 5.2% | -1.3% |
| Grape King Bio 1707.TW | Taiwan | $361M | -28% | -7% | 20% | 1.0× | -18.9% | +2.3% |
| TCI 8436.TWO | Taiwan | $320M | -24% | -2% | 18% | 1.2× | -13.0% | -3.2% |
| Boiron BOI.PA | France | $391M | -31% | -2% | 5% | 0.7× | -0.3% | -0.5% |
| Weihai Baihe Biology Technological 603102.SS | China | $314M | -20% | +18% | 14% | 1.1× | -10.2% | +9.6% |
| Tibet Aim Pharm 002826.SZ | China | $427M | -23% | +13% | 14% | 3.1× | 1.3% | +1.0% |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | 2.1× | -14.7% | +8.9% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | 10.2× | n/a | n/a |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | 3.4× | 3.0% | +7.0% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | 3.6× | 24.3% | +6.5% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 4.1× | 20.4% | +12.1% |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 5.2× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | 2.1× | n/a | n/a |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | 2.0× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | 1.6× | 4.9% | +13.5% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | n/a | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | 3.7× | 1.8% | +4.8% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 1.6× | 14.7% | +15.6% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | 2.5× | 3.6% | -1.3% |